報價延遲最少15分鐘:2024/12/23 22:23 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
14.13 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.02/-1.44
|
|
企業價值
595.78M
|
| 資產負債 |
|
每股賬面淨值
1.50
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
25.18M
|
|
每股收益
0.21
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/23 22:23 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery. |